Interagency Coordinating Committee on the Validation of Alternative Methods Biennial Progress Report: 2022-2023; Availability of Report, 75549-75550 [2024-20970]
Download as PDF
Federal Register / Vol. 89, No. 179 / Monday, September 16, 2024 / Notices
lotter on DSK11XQN23PROD with NOTICES1
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Ex Vivo
Models for Studies at the Intersection of HIV
and Poly-Substance Use.
Date: October 22, 2024.
Time: 12:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 827–4471,
ramadanir@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Exploratory Studies to Investigate
Mechanisms of HIV Infection, Replication,
Latency, and/or Pathogenesis in the Context
of Substance Use Disorders.
Date: November 7, 2024.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Soyoun Cho, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 594–9460,
Soyoun.cho@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: September 10, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–20917 Filed 9–13–24; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:23 Sep 13, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel, Multi-Scale
analysis of ADRD.
Date: October 21–22, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging, 5601
Fishers Ln, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Nijaguna Prasad, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Aging, 5601
Fishers Lane, Rm 2W200, Rockville, MD
20852, (301) 496–9667, prasadnb@
nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: September 10, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–20955 Filed 9–13–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Interagency Coordinating Committee
on the Validation of Alternative
Methods Biennial Progress Report:
2022–2023; Availability of Report
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Toxicology
Program (NTP) Interagency Center for
the Evaluation of Alternative
Toxicological Methods (NICEATM)
announces availability of the
SUMMARY:
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
75549
Interagency Coordinating Committee on
the Validation of Alternative Methods
(ICCVAM) Biennial Progress Report:
2022–2023.
ADDRESSES: The report is available at
https://ntp.niehs.nih.gov/go/
2023iccvamreport.
FOR FURTHER INFORMATION CONTACT: Dr.
Nicole Kleinstreuer, Director, National
Toxicology Program (NTP) Interagency
Center for the Evaluation of Alternative
Toxicological Methods (NICEATM),
email: nicole.kleinstreuer@nih.gov,
telephone: 984–287–3150.
SUPPLEMENTARY INFORMATION:
Background: The ICCVAM
Authorization Act of 2000 established
ICCVAM as a permanent interagency
committee of the National Institute of
Environmental Health Sciences (NIEHS)
under NICEATM. ICCVAM’s mission is
to facilitate development, validation,
and regulatory acceptance of new and
revised regulatory test methods that
reduce, refine, or replace the use of
animals in testing while maintaining
and promoting scientific quality and the
protection of human health, animal
health, and the environment.
A provision of the ICCVAM
Authorization Act states that ICCVAM
shall prepare ‘‘reports to be made
available to the public on its progress
under this Act.’’ The twelfth progress
report describing ICCVAM activities and
accomplishments from January 2022
through December 2023 is now
available.
Summary of Report Contents: Key
ICCVAM, ICCVAM agency, and
NICEATM accomplishments
summarized in the report include:
• Development of an updated
document on ‘‘Validation, Qualification,
and Regulatory Acceptance of New
Approach Methodologies,’’ by the
ICCVAM Validation Workgroup. This
document describes an approach to
validation of new approach
methodologies (NAMs) that reflects
modern toxicity testing, placing less
emphasis on replacement of in vivo
tests with a single alternative method
and more emphasis on integrating
results from multiple in vitro and in
chemico assays and in silico
approaches.
• Publication of articles describing
U.S. and international information
needs and testing requirements for
nanomaterials, ecotoxicity, and acute
systemic toxicity. An ICCVAM
workgroup also published an awardwinning article describing federal
agency application of in vitro to in vivo
extrapolation.
• Curation and publication of a
human skin sensitization database.
E:\FR\FM\16SEN1.SGM
16SEN1
lotter on DSK11XQN23PROD with NOTICES1
75550
Federal Register / Vol. 89, No. 179 / Monday, September 16, 2024 / Notices
ICCVAM agencies and NICEATM
collaborated with the German Federal
Institute of Risk Assessment to compile
the largest existing database of human
reference data for skin sensitization.
• Broadening applicability of defined
approaches for skin sensitization.
Following international acceptance of
defined approaches to skin
sensitization, ICCVAM agency scientists
evaluated use of defined approaches to
characterizing sensitization potential of
agrochemical formulations and
isothiazolinones, a type of preservative
used in consumer products.
• Establishment of an ICCVAM
workgroup to provide expertise in
identifying and evaluating NAMs to
predict toxicity of per- and
polyfluoroalkyl substances (PFAS).
• Development, updates, and training
on web tools and data resources for
chemical exploration and toxicity
prediction. The report describes tools
provided by NIEHS, the U.S.
Environmental Protection Agency, and
others, as well as training that has been
provided to support their use.
Availability of Report: The report is
available at https://ntp.niehs.nih.gov/
go/2023iccvamreport. Links to this
report and all past ICCVAM annual and
biennial reports are available at https://
ntp.niehs.nih.gov/go/iccvam-bien.
Background Information on ICCVAM
and NICEATM: ICCVAM is an
interagency committee composed of
representatives from 18 federal
regulatory and research agencies that
require, use, generate, or disseminate
toxicological and safety testing
information. ICCVAM conducts
technical evaluations of new, revised,
and alternative safety testing methods
and integrated testing strategies with
regulatory applicability. ICCVAM also
promotes the scientific validation and
regulatory acceptance of testing
methods that more accurately assess the
safety and hazards of chemicals and
products and replace, reduce, or refine
animal use.
The ICCVAM Authorization Act of
2000 (42 U.S.C. 285l–3) establishes
ICCVAM as a permanent interagency
committee of NIEHS and provides the
authority for ICCVAM involvement in
activities relevant to the development of
alternative test methods. Additional
information about ICCVAM can be
found at https://ntp.niehs.nih.gov/go/
iccvam.
NICEATM administers ICCVAM,
provides scientific and operational
support for ICCVAM-related activities,
and conducts and publishes analyses
and evaluations of data from new,
revised, and alternative testing
approaches. NICEATM and ICCVAM
VerDate Sep<11>2014
17:23 Sep 13, 2024
Jkt 262001
work collaboratively to evaluate new
and improved testing approaches
applicable to the needs of U.S. federal
agencies. NICEATM and ICCVAM
welcome the public nomination of new,
revised, and alternative test methods
and strategies for validation studies and
technical evaluations. Additional
information about NICEATM can be
found at https://ntp.niehs.nih.gov/go/
niceatm.
Dated: September 10, 2024.
Richard P. Woychik,
Director, National Institute of Environmental
Health Sciences and National Toxicology
Program, National Institutes of Health.
[FR Doc. 2024–20970 Filed 9–13–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Infrastructure
Development for Interdisciplinary Aging
Research.
Date: November 18, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging, 5601
Fishers Lane, Rockville, MD 20892 (Virtual
Meeting).
Contact Person: Lisa-Marie Tisdale Rowell,
Ph.D., Scientific Review Officer, National
Institute of Aging, National Institute of
Health, 5601 Fishers Lane, Rm. 1007G,
Rockville, MD 20892, (301) 594–5622,
wigfalllt@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
Dated: September 10, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–20950 Filed 9–13–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Alzheimer’s
Microbiome.
Date: October 10, 2024.
Time: 9:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging, 5601
Fishers Lane, Rockville, MD 20892 (Virtual
Meeting).
Contact Person: Dario Dieguez, Ph.D.,
Scientific Review Officer, National Institute
of Aging, National Institute of Health, 5601
Fishers Lane Rockville, MD 20852, (301)
827–3101, dario.dieguez@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: September 10, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–20951 Filed 9–13–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
E:\FR\FM\16SEN1.SGM
16SEN1
Agencies
[Federal Register Volume 89, Number 179 (Monday, September 16, 2024)]
[Notices]
[Pages 75549-75550]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-20970]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Interagency Coordinating Committee on the Validation of
Alternative Methods Biennial Progress Report: 2022-2023; Availability
of Report
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Toxicology Program (NTP) Interagency Center for
the Evaluation of Alternative Toxicological Methods (NICEATM) announces
availability of the Interagency Coordinating Committee on the
Validation of Alternative Methods (ICCVAM) Biennial Progress Report:
2022-2023.
ADDRESSES: The report is available at https://ntp.niehs.nih.gov/go/2023iccvamreport.
FOR FURTHER INFORMATION CONTACT: Dr. Nicole Kleinstreuer, Director,
National Toxicology Program (NTP) Interagency Center for the Evaluation
of Alternative Toxicological Methods (NICEATM), email:
[email protected], telephone: 984-287-3150.
SUPPLEMENTARY INFORMATION:
Background: The ICCVAM Authorization Act of 2000 established ICCVAM
as a permanent interagency committee of the National Institute of
Environmental Health Sciences (NIEHS) under NICEATM. ICCVAM's mission
is to facilitate development, validation, and regulatory acceptance of
new and revised regulatory test methods that reduce, refine, or replace
the use of animals in testing while maintaining and promoting
scientific quality and the protection of human health, animal health,
and the environment.
A provision of the ICCVAM Authorization Act states that ICCVAM
shall prepare ``reports to be made available to the public on its
progress under this Act.'' The twelfth progress report describing
ICCVAM activities and accomplishments from January 2022 through
December 2023 is now available.
Summary of Report Contents: Key ICCVAM, ICCVAM agency, and NICEATM
accomplishments summarized in the report include:
Development of an updated document on ``Validation,
Qualification, and Regulatory Acceptance of New Approach
Methodologies,'' by the ICCVAM Validation Workgroup. This document
describes an approach to validation of new approach methodologies
(NAMs) that reflects modern toxicity testing, placing less emphasis on
replacement of in vivo tests with a single alternative method and more
emphasis on integrating results from multiple in vitro and in chemico
assays and in silico approaches.
Publication of articles describing U.S. and international
information needs and testing requirements for nanomaterials,
ecotoxicity, and acute systemic toxicity. An ICCVAM workgroup also
published an award-winning article describing federal agency
application of in vitro to in vivo extrapolation.
Curation and publication of a human skin sensitization
database.
[[Page 75550]]
ICCVAM agencies and NICEATM collaborated with the German Federal
Institute of Risk Assessment to compile the largest existing database
of human reference data for skin sensitization.
Broadening applicability of defined approaches for skin
sensitization. Following international acceptance of defined approaches
to skin sensitization, ICCVAM agency scientists evaluated use of
defined approaches to characterizing sensitization potential of
agrochemical formulations and isothiazolinones, a type of preservative
used in consumer products.
Establishment of an ICCVAM workgroup to provide expertise
in identifying and evaluating NAMs to predict toxicity of per- and
polyfluoroalkyl substances (PFAS).
Development, updates, and training on web tools and data
resources for chemical exploration and toxicity prediction. The report
describes tools provided by NIEHS, the U.S. Environmental Protection
Agency, and others, as well as training that has been provided to
support their use.
Availability of Report: The report is available at https://ntp.niehs.nih.gov/go/2023iccvamreport. Links to this report and all
past ICCVAM annual and biennial reports are available at https://ntp.niehs.nih.gov/go/iccvam-bien.
Background Information on ICCVAM and NICEATM: ICCVAM is an
interagency committee composed of representatives from 18 federal
regulatory and research agencies that require, use, generate, or
disseminate toxicological and safety testing information. ICCVAM
conducts technical evaluations of new, revised, and alternative safety
testing methods and integrated testing strategies with regulatory
applicability. ICCVAM also promotes the scientific validation and
regulatory acceptance of testing methods that more accurately assess
the safety and hazards of chemicals and products and replace, reduce,
or refine animal use.
The ICCVAM Authorization Act of 2000 (42 U.S.C. 285l-3) establishes
ICCVAM as a permanent interagency committee of NIEHS and provides the
authority for ICCVAM involvement in activities relevant to the
development of alternative test methods. Additional information about
ICCVAM can be found at https://ntp.niehs.nih.gov/go/iccvam.
NICEATM administers ICCVAM, provides scientific and operational
support for ICCVAM-related activities, and conducts and publishes
analyses and evaluations of data from new, revised, and alternative
testing approaches. NICEATM and ICCVAM work collaboratively to evaluate
new and improved testing approaches applicable to the needs of U.S.
federal agencies. NICEATM and ICCVAM welcome the public nomination of
new, revised, and alternative test methods and strategies for
validation studies and technical evaluations. Additional information
about NICEATM can be found at https://ntp.niehs.nih.gov/go/niceatm.
Dated: September 10, 2024.
Richard P. Woychik,
Director, National Institute of Environmental Health Sciences and
National Toxicology Program, National Institutes of Health.
[FR Doc. 2024-20970 Filed 9-13-24; 8:45 am]
BILLING CODE 4140-01-P